Genzyme's Termeer: Worst Biotech CEO of '09
Genzyme CEO Henri Termeer is Adam Feuerstein's Worst Biotech CEO of the Year for 2009.
12:31PM 11/17/09
Biotech Stock Mailbag: Oncothyreon
Readers write in about Oncothyreon, Progenics, Chelsea Therapeutics and more.
07:00AM 10/16/09
Biotech Scorecard: My Best and Worst Calls
Biotech expert Adam Feuerstein grades his hits and misses for 2008.
06:59AM 01/02/09
Here's a look back at the hits, misses and notable moments from 2008.
12:20PM 12/29/08
Elan's Martin Named Worst Biotech CEO of '08
Kelly Martin is taking home the Nance Trophy for oustanding achievement in loss of shareholder value, overstated optimism and abject incompetence under pressure.
10:44AM 12/11/08
Biotech Mailbag: NeurogesX Patchy at Best
It's not clear how this tiny biotech's pain patch can compete with a host of rivals, large and small.
01:01PM 12/05/08
Biotech Mailbag: NeurogesX Patchy at Best (RealMoney.com $)
It's not clear how this tiny biotech's pain patch can compete with a host of rivals, large and small.
07:00AM 12/05/08
Biotech Stock-Picking: Incyte, Celgene
How much do you know about investing in biotech companies? Go beyond the hype with TheStreet.com
06:37PM 10/27/08
Biotech Mailbag: Study Boosts ImmunoGen
Genentech is advancing T-DM1, which uses ImmunoGen technology, into a phase III study as a second-line treatment for Her-2 positive metastatic breast cancer.
11:37AM 10/17/08
Genentech Study Good News for ImmunoGen (RealMoney.com $)
Genentech is advancing T-DM1, which uses ImmunoGen technology, into a phase III study as a second-line treatment for Her-2 positive metastatic breast cancer.
07:06AM 10/17/08
Biotech Mailbag: Epix Pharmaceuticals
It may be best to wait for data from two clinical studies on Alzheimer's drug PRX-03140 before making any predictions about its prospects.
06:59AM 09/05/08
Introgen Critically Hurt by FDA Advexin Snub
The regulator refused to accept an approval application for the gene therapy cancer drug, dealing a devastating blow to the company.
11:15AM 09/02/08
Biotech-Stock Mailbag: Genentech
If Roche is serious about buying the company, it will need to do much better than $89 a share.
10:09AM 08/15/08



Connect with TheStreet